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ABSTRACT
Immune responses of natural killer (NK) cell are controlled by the balance between activating and inhibitory receptors, but the
expression of these receptors varies between cells within an individual. Although NK cells are a component of the innate immune
system, particular NK cell subsets expressing Ly49H are positively selected and increase in frequency in response to cytomegalo-
virus infection in mice. Recent evidence suggests that in humans certain NK subsets also have an increased frequency in the
blood of human cytomegalovirus (HCMV)-infected individuals. However, whether these subsets differ in their capacity of direct
control of HCMV-infected cells remains unclear. In this study, we developed a novel in vitro assay to assess whether human NK
cell subsets have differential abilities to inhibit HCMV growth and dissemination. NK cells expressing or lacking NKG2C did not
display any differences in controlling viral dissemination. However, when in vitro-expanded NK cells were used, cells expressing
or lacking the inhibitory receptor leukocyte immunoglobulin-like receptor 1 (LIR1) were differentially able to control dissemi-
nation. Surprisingly, the ability of LIR1NK cells to control virus spread differed between HCMV viral strains, and this phe-
nomenon was dependent on amino acid sequences within the viral ligand UL18. Together, the results here outline an in vitro
technique to compare the long-term immune responses of different human NK cell subsets and suggest, for the first time, that
phenotypically defined human NK cell subsets may differentially recognize HCMV infections.
IMPORTANCE
HCMV infection is ubiquitous in most populations; it is not cleared by the host after primary infection but persists for life. The
innate and adaptive immune systems control the spread of virus, for which natural killer (NK) cells play a pivotal role. NK cells
can respond to HCMV infection by rapid, short-term, nonspecific innate responses, but evidence frommurine studies suggested
that NK cells may display long-term, memory-like responses to murine cytomegalovirus infection. In this study, we developed a
new assay that examines human NK cell subsets that have been suggested to play a long-termmemory-like response to HCMV
infection. We show that changes in an HCMV viral protein that interacts with an NK cell receptor can change the ability of NK
cell subsets to control HCMVwhile the acquisition of another receptor has no effect on virus control.
Following primary human cytomegalovirus (HCMV) infec-tion, lytic viral replication is controlled by the host immune
response, which includes humoral (1, 2), innate (3, 4), and adap-
tive (5–7) cellular immune responses. Despite this robust immune
response, the virus is still able to establish latency in myeloid pro-
genitor cells (8, 9). Virus can reactivate when these cells differen-
tiate to mature dendritic cells, and as such the virus is able to
persist for the lifetime of the host. Primary infection of healthy
immunocompetent individuals is most often asymptomatic, but
the virus can cause severe diseases in immunocompromised
transplant patients, immunocompromised patients with AIDS,
and the immune immature, particularly following in utero in-
fection (10–14).
Natural killer (NK) cells are defined as a component of the
innate immune system, as they do not undergo somatic DNA
rearrangements in order to express highly diverse antigen recep-
tors in the same manner as B and T cells do (15). Instead, NK cells
express a wide variety of activating and/or inhibitory receptors
that are able to bind cellular ligands, some of which are normally
expressed while others are induced by infection or transformation
(reviewed in reference 16). The balance between activating and
inhibitory signals determines if an NK cell is activated and exerts
an effector function or not. NK cells are implicated in control of
herpesvirus infections, since individuals with rare NK cell defects
have been shown to have difficulty controlling multiple different
herpesvirus infections, including HCMV (17, 18).
In order to avoid this NK cell response, HCMV encodes mul-
tiple proteins that modulate NK cell recognition of infected cells
(19, 20). These NK evasion functions act by preventing cellular
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ligands binding to activating NK cell receptors (UL16, UL141,
UL142, US18, US20, US9 [21–27], and miR-UL112 [21]), by ex-
pressing proteins that engage inhibitory NK cell receptors (UL18
[28], UL40 [20, 29]), and UL83 [30]), and by modifying the struc-
ture of the immune synapse (UL135 [31]).
However, NK cells are not homogeneous; instead, numerous
different NK cell subsets exist within a given individual, since in-
dividual activating and inhibitory NK receptors are independently
expressed in varied combinations on different cells. Murine stud-
ies have shown that the interaction between murine cytomegalo-
virus (MCMV) protein m157 and the activating Ly49H receptor
on murine NK cells leads to direct activation of NK cells and the
control of MCMV disease (32). In contrast, the only known ex-
ample of direct NK cell receptor binding with HCMV protein is
the interaction of leukocyte immunoglobulin-like receptor 1
(LIR1, now commonly known as LILRB1), an inhibitory receptor
that normally binds to human major histocompatibility complex
class I (MHC-I) molecules, with the HCMV protein UL18, a viral
homolog of cellular MHC-I-like molecules (33, 34). Early work on
the UL18 protein from HCMV strain AD169 suggested that it
could enhance cytotoxic killing by an NK cell line against an Ep-
stein-Barr virus (EBV)-infected 293 cell line target in chromium
release assays (35); however, these experiments did not consider
the level of expression of LIR1 on NK cells. Subsequently,
Prod’homme et al. (28) showed that the UL18 protein from
HCMV strain AD169 actually lowered the short-term cytotoxic
responses of NK cells, but only if they expressed LIR1 (LIR1),
leading to the conclusion that UL18 was an immunoregulatory
protein that inhibited NK cells from clearing HCMV lytically in-
fected cells (28).
The activating C-type lectin receptor CD94/NKG2C, which
normally binds to human HLA-E, can also bind with HCMV
UL18 protein but with 1,000-fold-weaker affinity than LIR1 (36).
NKG2CNK cells have been shown to be preferentially expanded
in HCMV-seropositive individuals (37–42). In vitro experiments
demonstrated that HCMV can induce expansion of CD94/
NKG2C NK cells (43), and these cells show enhanced cytotoxic
responses against HCMV-infected cells in the presence of HCMV-
specific antibodies (44). Except UL18, no other HCMV viral li-
gand has been shown to bind directly with NKG2C/CD94. More-
over, although these reports support a strong correlation between
an increase in NKG2CNK cells and HCMV serostatus (reviewed
in reference 16), no report to date has determined whether the
expression of NKG2C on NK cells, in the absence of HCMV-
seropositive donor serum (44), leads to better control of virus.
So far, the interpretation of the role of LIR1 and NKG2C re-
ceptors has focused mainly on NK cell degranulation and cytotox-
icity effector functions over short-term (4- to 6-h) coculturing of
NK cells with infected target cells. However, NK cells also secrete
inflammatory cytokines and can replicate after activation, and
these can also influence virus replication (16). Thus, longer-term
assessment of antiviral activity of NK cells and particularly of NK
cell subpopulations would be a valuable method to further under-
stand the interaction of NK cells with HCMV-infected cells.
We have recently developed and utilized such a viral dissemi-
nation assay (VDA) to examine the antiviral activity of HCMV-
specific T cells (45). In this study, we have used a VDA in conjunc-
tion with coculture of different NK cell subsets in order to
compare their abilities to inhibit HCMV dissemination. In vitro-
expanded LIR1 NK cells controlled the spread of laboratory
HCMV strain AD169 less effectively than did LIR1-nonexpressing
(LIR1) NK cells, in good agreement with the NK cell effector
function analyses by Prod’homme et al. (28). However, when low-
passage-number/clinical strains TB40/e and Merlin were used in
the VDA, this was not the case. In fact, LIR1 NK cells displayed
stronger control of virus spreading than did LIR1 NK cells, and
this was observed in multiple different donors. Using the pub-
lished crystal structure of the LIR1-UL18/B2m complex to inform
the generation of specific HCMV mutants, we identified three
amino acids in the viral UL18 protein that were responsible for
this phenomenon. Furthermore, using NK cell subsets expressing
LIR1 and NKG2C, we demonstrated that LIR1, rather than
NKG2C, plays the dominant role in influencing the long-term
responses of LIR1 NK cells during HCMV dissemination.
MATERIALS AND METHODS
Donor sample collection and isolation. Heparinized peripheral blood
was collected from healthy donors. HCMV serostatus was determined
using an IgG enzyme-linked immunosorbent assay (Trinity Biotech, Did-
cot, United Kingdom). Ten HCMV-seronegative and five HCMV-sero-
positive donors were included in this study. Ethical approval involving
donor peripheral blood was obtained from the Addenbrookes National
Health Service Hospital Trust institutional review board (Cambridge Re-
search Ethics Committee) for this study. Informed written consent was
obtained from all recipients in accordance with the Declaration of Hel-
sinki (LREC 97/092).
Cells and viruses. The human foreskin fibroblast (HFF) cell line was
obtained from a commercial company (Invitrogen, Paisley, United King-
dom) and was cultured in MEM-10, consisting of Eagle’s minimal essen-
tial medium (EMEM; Life Technologies) supplemented with 10% fetal
calf serum (PAA, Linz, Austria), 100,000 IU/ml penicillin (Life Technol-
ogies), and 100 mg/ml streptomycin (Life Technologies). The strains of
HCMV used in these studies were AD169, AD169 with the UL18 open
reading frame (ORF) deleted (AD169-UL18) (46), strain Merlin con-
taining a green fluorescent protein (GFP)-UL32 fusion protein (Merlin)
(47), Merlin-GFP-UL32 with UL18 ORF deletion (Merlin-UL18), and
TB40/e-GFP-UL32 (TB40/e; kind gift of Christian Sinzger). In addition,
the UL18 sequence-modified virus strains (AD169-UL18Merlin and Mer-
lin-UL18AD169) were generated by recombineering as previously de-
scribed (48) using the primers listed in Table 1. The method used to
generate the mutant virus isolates does not lead to the loss of US2-US6
HCMV genes.
Sequencing of HCMVUL18 ORF. DNA was extracted from HCMV-
infected fibroblasts using the DNeasy-blood and tissue kit (Qiagen). A
30-cycle PCR was performed to amplify viral UL18 ORF using the forward
primers shown in Table 1 and under conditions previously described (49).
Samples were sequenced by the Source Bioscience Sequencing Team,
Cambridge, United Kingdom.
Preparation of in vitro-expanded NK cells. Fresh peripheral venous
blood was obtained by venipuncture, performed by a trained phleboto-
mist. Peripheral blood mononuclear cells (PBMC) were isolated from
fresh peripheral venous blood by Ficoll Hypaque density gradient centrif-
ugation (Axis-Shield, Oslo, Norway) as previously described (50). NK
cells were purified from PBMC, using the EasySep-Human NK cell en-
richment kit (StemCell Technologies). In vitro-expanded, activated NK
cell lines (referred to here as in vitro-expanded NK cells) were then gen-
erated from ex vivo NK cells by coculturing with irradiated allogeneic
Epstein-Barr virus (EBV)-transformed B cell lines and irradiated autolo-
gous PBMC using methods previously described (24). The cell lines were
cultured in RPMI-10 (described earlier) with 25 IU/ml interleukin-2
(IL-2; National Institute for Biological Standards and Controls) replen-
ished every 5 days.
Preparationof sortedNKcell subsets. In vitro-expanded NK cell lines
were stained with mouse anti-human CD56-Pacific Blue (PB) or fluores-
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cein isothiocyanate (FITC; eBioscience, United Kingdom), CD3-PerCP/
Cy5.5 (Biolegend UK), LIR1/CD85j-phycoerythrin (PE) (Biolegend UK),
and NKG2C-allophycocyanin (APC) (Biolegend UK) antibodies. CD56
CD3 NK cells were sorted into different populations using a FACSJazz
cell sorter (where FACS stands for fluorescence-activated cell sorter) run-
ning FACS DIVA software (Becton Dickinson, United Kingdom).
CD107a degranulation assays. K562 cells (1  106) or HCMV-in-
fected fibroblasts (subjected to overnight infection with TB40/e at a
multiplicity of infection [MOI] of 5) were cocultured with in vitro-
expanded NK cells at a ratio of 1:1 in 50 l RPMI-10 and incubated at
37°C and 5% CO2. Monensin (BioLegend) was added at a 1:1,000
dilution after 1 h of coincubation and further incubated for 4 h at 37°C
and 5% CO2. Cells were washed in phosphate-buffered saline (PBS)
before staining with anti-human CD56 (APC), CD3-FITC, and
CD107a PerCP/Cy5.5 antibodies (Biolegend UK) before being ana-
lyzed by flow cytometry using FACSCalibur (BD) running CellQuest
software (BD). Results were analyzed using FlowJo 7.6 (Tree Star Inc.,
Ashland, OR, USA).
CCL4 cytokine ELISAs. In vitro-expanded NK cells were cocultured
overnight with K562 cells or HCMV-infected fibroblasts (overnight infec-
tion with TB40/e at an MOI of 5) using the method described earlier for
the CD107a assays, but without monensin. The cocultures were left for 12
h before the supernatant was harvested, and the CCL4 cytokine concen-
tration was measured using an enzyme-linked immunosorbent assay
(ELISA) kit (R&D systems).
In vitro viral dissemination assay. The ability of NK cell subsets
(sorted based on differences in specific receptor expression) to control the
spread of HCMV in vitro was measured. Allogeneic HFF cells were seeded
in 24-well flat-bottom culture plates (LifeSciences, United Kingdom) to
be 80 to 90% confluent when they were infected with virus at an MOI of
0.1 overnight. Rested in vitro-expanded NK cells were harvested, washed,
stained, sorted, and resuspended in MEM-10 and then added to the in-
fected fibroblasts at an NK cell-to-fibroblast ratio of 1.25:1, 0.625:1, or
0.3125:1 in 1 ml MEM-10 and incubated at 37°C and 5% CO2. Assessment
of viral dissemination was performed at 9 days postincubation. GFP ex-
pression (TB40/e and Merlin) was detected by either fluorescence micros-
copy or flow cytometry. When HCMV AD169 was used, fibroblasts were
stained intracellularly with anti-CMV immunoelectrophoresis (IE)-Alexa
Fluor488 antibody (Millipore) using the Cell Fixation/Permeabilization
kit (An-Der-Grub BioResearch). Fibroblasts were fixed with a 2% para-
formaldehyde–PBS solution and analyzed using flow cytometry as de-
scribed earlier.
Viral spread in each well was determined as a percentage of control
wells lacking NK cells, using the following equation: ([Experimental % of
infected cells background % of HFF-only control]/[% of infected HFF
control without NK cells background % of HFF-only control]) 100.
Phylogenetic tree. BioEdit Sequencing Alignment Editor was used for
sequence analysis. The evolutionary phylogenetic trees were computed
using Molecular Evolutionary Genetics Analysis (MEGA).
Statistics. Statistical analysis was performed using GraphPad Prism
version 4.00 for Windows (GraphPad Software, San Diego, CA). Proba-
bilities were calculated with one-way or two-way analysis of variance
(ANOVA) paired Friedman test in the viral dissemination assay, assuming
not-repeated measures. Standard t test analysis was used to analyze the
cytokine CCL4 release assay and CD107a degranulation assay. Results
with P values of0.05 were considered significant.
RESULTS
Control of different strains ofHCMVdissemination by in vitro-
expanded primary NK cell lines. We have previously developed
an assay to measure T cell-mediated antiviral activity based on the
inhibition of HCMV dissemination through a permissive fibro-
blast monolayer (51, 52). In addition, a focal expression assay that
is similar in concept to our viral dissemination assay (VDA) has
recently been described by others (52) and used to examine anti-
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FIG 1 Establishment of viral dissemination assay. (A) Human fibroblasts (HFFs) infected with HCMV strain TB40/e UL32-GFP at an MOI of 0.1 and in
vitro-expanded NK cells were cocultured for 9 days at various effector-to-target (E/T) ratios, starting from 1.25:1 to 0.3125:1, at 37°C and 5% CO2. NK cells were
then washed off, and the HFFs were observed by fluorescence microscopy (top panel) or following trypsinization analyzed by flow cytometry (bottom panel).
Representative dot plots show the results from uninfected and infected controls and the change percentage of fluorescent cells following coincubation with
different ratios of NK cells to HFFs. (B) The assay was also performed using HFFs infected with untagged AD169 at an MOI of 0.1. The cells were stained
intracellularly with anti-IE-Alexafluor488 antibodies before being analyzed by flow cytometry. (C) Summary results of dissemination assays on NK cells derived
from 7 donors using AD169-infected HFFs, from 4 donors using TB40/e-infected HFFs, and from 9 donors using Merlin-infected HFFs. The MOI used was 0.1,
and various effector-to-target (E/T) ratios from 1.25:1 to 0.3125:1 were used. At the end of the assay, TB40/e-infected or Merlin-infected HFFs were analyzed by
flow cytometry without additional staining, while AD169-infected HFFs were stained with anti-IE-Alexa Fluor 488 antibody before analysis by flow cytometry.
Data were analyzed by one-way ANOVA, and significant results (*, P 0.05; **, P 0.01) are indicated. (D) Three separate dissemination assays using HCMV
strain AD169, TB40/e, or Merlin at an MOI of 0.1 were conducted using in vitro-expanded NK cells from either a seropositive donor (donor 319) or a seronegative
donor (donor 401). The data were normalized according to the uninfected and infected controls. The black triangles are results from Merlin-infected HFF; gray
triangles are TB40/e-infected HFF; and gray squares are AD169-infected HFF. Each data point represents 3 independent readouts, and error bars represent the
standard errors of the means (SEM). Data were analyzed by two-way ANOVA, and significant results (*, P 0.05; **, P 0.01) are indicated.
Chen et al.
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FIG 2 NK cells expressing LIR1 have effector cellular functions similar to those of LIR1-nonexpressing NK cells but are more able to control viral dissemination
of HCMV strains TB40/e and Merlin. (A) In vitro-expanded NK cells were stained with anti-CD3, -CD56, and -LIR1 antibodies and sorted by flow cytometry.
CD56 CD3 NK cells were first collected (NK) before further sorting into LIR1 (LIR1 NK) and LIR1 (LIR1 NK) subsets based on LIR1 expression.
Representative dot plots of the NK cells before and after sorting are shown. (B) NK, LIR1 NK and LIR1 NK cells were cocultured with K562 target cells. The
Differential Responses of LIR1 NK Cells to HCMV
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HCMV activity by NK cells (45). We wished to use our VDA to
study the antiviral activity of different NK cell subsets, as defined
by specific cell surface markers.
In order to validate this approach, we used the VDA against
different strains of HCMV to determine if in vitro-expanded NK
cells were able to control the spread of high-passage-number lab-
oratory-adapted (AD169) and low-passage-number isolates of
HCMV TB40/e and Merlin. The results clearly show that NK cells
were able to prevent viral spread in an effector-to-target ratio (E/
T)-dependent fashion. This was visualized by fluorescence mi-
croscopy and quantified by flow cytometry, either by GFP if the
virus expressed GFP (Fig. 1A) or by anti-HCMV IE antigen stain-
ing with a fluorescent antibody if it did not (Fig. 1B).
High-passage-number strains such as AD169 lack multiple im-
mune evasion genes. This renders AD169-infected cells more sus-
ceptible to NK cell-mediated lysis than low-passage-number
HCMV isolates such as TB40/e or Merlin in short-term cytotox-
icity assays (53, 54). In order to compare VDA results between
different strains of virus, data for each virus were normalized
against their own positive (HCMV-infected HFFs without NK
cells) and negative (noninfected HFFs) controls. The positive con-
trol represents the maximal spread of the virus over the course of
the assay, while the negative control is the background fluores-
cence.
Across multiple donors, it was clear that the virus spread of
AD169 (n  4) was significantly reduced compared to those of
Merlin (n  9) and TB40/e (n  7), implying that polyclonally
activated NK cells were significantly more efficient at controlling
the spread of AD169 (Fig. 1C). In addition, TB40/e was controlled
less well than Merlin at the highest E/T ratio of 1.25:1. A similar
trend was evident at the lower ratios, although this was not statis-
tically significant (Fig. 1C). Importantly, NK cells still exerted
some degree of control over Merlin, as viral spread did not reach
100% for any of the E/T ratios tested (Fig. 1C). We also performed
VDAs using in vitro-expanded NK cells derived from either an
HCMV-seropositive or -seronegative donor (Fig. 1D). No major
differences were seen between the polyclonal NK cells from these
donors, with cells from both being significantly more efficient at
controlling the spread of AD169 than either TB40/e or Merlin.
Taken together, these results demonstrate that, using this NK
cell VDA, a low-passage-number isolate of HCMV (Merlin) was
resistant to NK cell-mediated control, while an isolate lacking NK
immune evasion genes (AD169) was less resistant. Despite low-
passage-number strains being more resistant to NK cell control,
polyclonal NK cells did still exert some degree of control, indicat-
ing that this assay represented a useful method to study the anti-
viral properties of different subsets of NK cells as well as the ability
of different HCMV isolates to affect NK cell recognition.
Comparison of LIR1 and LIR1 NK cell control of HCMV
dissemination. The VDA was able to identify differences in the
ability of NK cells to control different HCMV strains; we next
wanted to use the assay to determine if certain NK cell subsets, as
defined by surface expression of particular phenotypic markers,
were more efficient at controlling HCMV infection. The HCMV
MHC-I homolog UL18 (specifically from strain AD169) has al-
ready been shown to decrease direct NK cell cytotoxic responses,
as it is able to bind the inhibitory receptor LIR1 present on some
NK cell subsets (28). As such, AD169 should be less well controlled
by LIR1 NK cells (which would be inhibited by HCMV UL18
protein expression) than by LIR1 NK cells (which would not be
inhibited by UL18 [28]).
Primary in vitro-expanded NK cell lines were generated from
different donors; NK cells were sorted as CD3 CD56 cells be-
fore sorting into subsets based on their LIR1 expression, achiev-
ing	95% purity after sorting (Fig. 2A). To ensure that the subsets
maintained their effector functions, postsorting cytotoxicity and
cytokine secretion against the classic K562 target cells were exam-
ined (55). NK cell cytotoxicity was determined by CD107a de-
granulation assay, and cytokine production was assessed by mea-
suring CCL4 production, one of the earliest inflammatory
cytokines produced following NK cell activation (56). While the
NK cell lines were capable of generating gamma interferon
(IFN-
) against K562 target cells, the response was modest, be-
tween 20 and 30 pg/ml. The CCL4 response was more substantial
at 400 pg/ml and was also elicited by HCMV-infected target cells;
therefore, we measured CCL4 for all the subsets, as it provided a
better dynamic range in order to determine if cell sorting had
caused differences in the sorted subsets.
Both LIR1 and LIR1 subsets had a cytotoxic response and
level of CCL4 secretion similar to those of the unsorted NK cell
line from which they were derived (Fig. 2B). Thus, NK cells main-
tain their cellular functions after sorting, and this also suggests
that engagement of anti-LIR1 antibodies did not cause inhibition
of LIR1 NK cell effector functions.
The LIR1 and LIR1NK cell subsets were then used in a VDA
against AD169-infected HFFs. As predicted, the results show that
there was a greater percentage of viral spread in the presence of
LIR1 NK cells than LIR1 NK cells (Fig. 2C). The VDA was also
performed using HFFs infected with the low-passage-number
HCMV strains TB40/e and Merlin. Surprisingly, different results
were obtained. Against these strains, LIR1 NK cells demon-
strated more efficient virus control than LIR1 NK cells (Fig. 2D
and E). The same results were observed for three independent
donor NK cell lines tested (Fig. 2C to E). Thus, differences be-
tween HCMV strains can affect the ability of NK cell subsets to
control virus spread.
Deletion ofHCMVUL18ORF abolishes the differential con-
trols mediated by LIR1 and LIR1 NK cells. We next investi-
gated whether the above phenomenon (Fig. 2C to E) was caused
by the viral UL18 protein. If it was due to the interaction of UL18
on HCMV-infected cells with LIR1 on NK cells, the difference
should be negated if a virus with UL18 deleted or a blocking anti-
NK cell-to-target ratio is 1:1. K562 cells and NK cells only are the controls. After culturing for 5 h, the percentages of CD107a cells were measured by flow
cytometry. CCL4 concentration is quantified using ELISA after culturing overnight. Each data point represents the mean value of 3 repeats, and error bars
represent SEM. The experiment was preformed using three different donors (n 3), and the results showed the average values analyzed by the Student t test.
Nonsignificant results (NS; P	 0.05) are indicated. (C) LIR1 and LIR1NK cell subsets were cocultured with human HFFs infected with HCMV strain AD169,
TB40/e, or Merlin at an MOI of 0.1 in a viral dissemination assay. The NK cell-to-target ratios are 1.25:1, 0.625:1, and 0.312:1. The data were normalized
according to the uninfected and infected controls. The gray triangles are results from LIR1NK cells, and black squares are the results from LIRNK cells. Each
data point represents 3 independent readouts, and error bars represent SEM. In total, each assay was repeated three times (n  3) using NK cells from three
different donors. Data were analyzed by two-way ANOVA, and significant results (*, P 0.05; **, P 0.01) are indicated.
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body to LIR1 were used in these assays. While LIR1-blocking
antibodies are available, they could deliver inhibitory signals
through LIR1, and we were concerned that the antibody concen-
trations could be maintained over the long period of this assay;
therefore, we determined the involvement of UL18 by using UL18
deletion mutants of both AD169 and Merlin.
VDAs were conducted using HCMV AD169-UL18 and Mer-
lin-UL18 viruses as well as their parental strains. As before,
LIR1NK cells were less able to control the spread of AD169 than
were LIR1 NK cells; however, when AD169-UL18 was used,
this difference was eliminated (Fig. 3A). In donor 410, the LIR1
NK cells exhibit the same level of viral control for both AD169 and
AD169-UL18 viruses; however, the major change occurs with
LIR1 NK cells, which exert better control over AD169-UL18
virus than AD169, in agreement with results from the other inde-
pendent donors. In donor 319, we noted a discrepancy in that
both LIR1 and LIR1 cells exerted greater control when UL18
had been deleted in this experiment. However, this seems to be
donor specific (donor-to-donor variation) rather than virus spe-
cific, as it does not occur in other donors (donor 405, for exam-
ple), indicating that it is unlikely to be due to additional changes in
the AD169-UL18 strain. Nevertheless, although with donor 319
the AD169-UL18 strain had a lower spread than expected in the
presence of both LIR1 and LIR1 NK cells, the two subsets did
maintain the same pattern as the other donors (i.e., there were no
significant differences between the subsets once UL18 was re-
moved). Because of this, we feel that the data support the conclu-
sion that removal of UL18 from AD169 allows better control by
LIR1 NK cells. When HCMV strain Merlin was used, LIR1 NK
cells controlled virus spread better than LIR1 NK cells, again
independently verifying our previous observations (Fig. 2). Simi-
lar to what was observed with AD169, deletion of UL18 from this
virus strain also resulted in the elimination of this difference (Fig.
3B). The experiments were repeated using NK cells derived from
four independent donors, and in all but one donor the same pat-
terns of results were observed (Fig. 3A and B): donor 302 showed
a significant difference between subsets when AD169-UL18 was
used (Fig. 3A), while donor 405 showed a small but significant
difference between the subsets when Merlin-UL18 was used
(Fig. 3B).
The results suggested that UL18 was responsible for the effects
on LIR1 and LIR1 NK cell control of viral dissemination and
further suggested that UL18 from different strains affected NK cell
subsets in a different manner. The crystal structure of the UL18
protein interacting with LIR1 has been determined by Yang et al.
(57) and shows that the interactions occur between the3 domain
of UL18 and LIR1 (57). There are three sites of interactions be-
tween UL18 and LIR1, compared with two sites between human
MHC-I and LIR1, which has been suggested as the reason for a
1,000-fold-higher binding affinity observed between UL18 and
LIR1 than MHC-I (57).
To investigate if strain-dependent sequence variability was re-
sponsible for the differences observed in LIR1NK cell control of
HCMV dissemination, UL18 sequences from GenBank were iden-
tified and the amino acid sequences within the 3 region were
aligned (Fig. 3C). In this region, HCMV strains TB40/e and Mer-
lin have a sequence of NKAPDD, while AD169 has DKVPED.
These three amino acid differences (N/D, A/V, and D/E) are lo-
cated adjacent to the additional site of interaction with LIR1 pro-
posed by Yang et al. (57), which results in the increased binding
affinity compared to the MHC-I-LIR1 interaction.
Although these amino acids have not been implicated in the
direct interaction between UL18 and LIR (57), we hypothesized
that they may be of significance because 12 of 13 unique UL18
sequences in the database have either amino acid sequences of
NKAPDD or DKVPED (Fig. 3B). We further constructed a neigh-
boring-phylogenic tree to analyze the similarity in the3 domains
among the HCMV viral strains (Fig. 3D). The alignment shows
that the two UL18 sequences from TB40/e and Merlin were closely
related to each other while the AD169 sequence was located in a
different cluster (Fig. 3D). There were no differences between the
1 and 2 regions of UL18 proteins from these three viruses (not
shown).
UL18 sequence variability affects NK cell control of HCMV
dissemination. If the 3 amino acids identified (Fig. 3) were re-
sponsible for the differences observed in control of viral dissemi-
nation, mutating the UL18 from the sequence of one virus strain
to the sequence of the other should reverse the pattern of control
observed with LIR1 and LIR1 NK cells. Recombineering was
used to mutate the AD169 sequence from DKVPED to the Merlin
sequence NKAPDD (AD169-UL18Merlin), a reciprocal mutation
was made to the Merlin sequence from NKAPDD to the AD169
sequence DKVPED (Merlin-UL18AD169), and mutant UL18 se-
quences were verified by PCR amplification and sequencing (Fig.
4A). These mutant viruses were used to infect human fibroblasts,
and VDAs were performed using LIR1 and LIR1 NK cells de-
rived from multiple independent donors.
As previously observed, LIR1 NK cells from four different
donors were less effective at controlling AD169 dissemination
(Fig. 4B, left column). However, when the three amino acids were
mutated to the Merlin sequence, the pattern of recognition was
changed to that previously seen with Merlin virus, whereby LIR1
NK cells controlled virus spread more effectively than LIR1 NK
cells (Fig. 4B, right column). Likewise, as before, LIR1 NK cells
FIG 3 UL18 proteins from different HCMV strains influence the control of virus dissemination by LIR1 NK cells. (A) Sixty-seven sequences of HCMV UL18
proteins were identified from the NCBI protein database (http://www.ncbi.nlm.nih.gov). Six sequences had a truncation and are not included in the alignment.
Thirteen unique amino acid sequences of the 3 region of UL18 were identified. Each unique sequence is shown only once in the alignment and is represented
by a unique letter. The number following the letter in the sequence name represents the number of times the sequence has appeared in the database. Gray boxes
indicate the sites interacting with LIR1 as suggested by the crystal structure (57), while the black line indicates the key differences between the UL18 of AD169 and
Merlin strains. (B) Results of the neighbor-phylogenic tree analysis showing the relationship between the sequences based on the protein3 region. Twenty virus
strains have an NKAPED sequence, 37 have DKVPED, and 4 have DKAPDD. (C) NK cells from four different donors (n  4) were sorted based on LIR1
expression as previously described before being cocultured in a viral dissemination assay with HFFs infected with HCMV strain AD169 or AD169-UL18 at an
MOI of 0.1. Infected cells were stained with IE-Alexa Fluor 488 antibodies before analysis using flow cytometry. (D) The viral dissemination assay was repeated
with NK cells from four different donors (n 4) sorted based on LIR1 expression and cocultured with HFFs infected with HCMV strain Merlin or Merlin-UL18
at an MOI of 0.1. Infected HFFs were analyzed on the basis of UL32-GFP fluorescence. In panels C and D, the gray triangles are results from LIR1NK cells; black
squares are the results from LIR NK cells. The NK cell-to-target ratios range from 1.25:1, 0.625:1, and 0.312:1. Each data point represents 3 independent
readouts. The data were analyzed using two-way ANOVA, error bars represent SEM, and significant results (*, P 0.05; **, P 0.01) are indicated.
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from all donors were more effective at controlling Merlin dissem-
ination than LIR1 NK cells (Fig. 4C, left column), and the mu-
tation of three amino acids within UL18 of Merlin to the AD169
sequence reversed this pattern, whereby LIR1 NK cells con-
trolled virus spread less effectively than LIR1 NK cells (Fig. 4C,
right column). Together, these results suggest that LIR1-express-
ing NK cell subsets can differentially control HCMV but that this
ability can be altered by variation in the sequence of UL18, the
viral ligand to LIR1.
NKG2C-expressing NK cells influence the functional re-
sponses of NK cells but not the dissemination of HCMV. It has
been suggested that receptors other than LIR1 may also influence
the activity of NK cells against HCMV-infected cells, in particular
the activating receptor NKG2C. Numerous reports have shown a
FIG 4 Mutation of HCMV UL18 proteins causes changes in the control of viral dissemination by NK cells. (A) A PCR and sequencing on the 3 region of UL18
was performed to check the mutant viruses AD169-UL18Merlin and Merlin-UL18AD169 and compare them with parental strains. The amino acid alignment is
shown with the altered sites indicated. Viral dissemination assays were then carried out using NK cells from four different donors (n 4) cocultured with HFFs
infected at an MOI of 0.1 with virus strains AD169 and AD169-UL18Merlin (B) or Merlin and Merlin-UL18AD169 virus (C). AD169- and AD169-UL18Merlin-
infected HFFs were stained with IE-Alexa Fluor 488 antibodies before analysis using flow cytometry. Merlin or Merlin-UL18AD169 virus-infected HFFs
expressed GFP and did not require additional staining. The NK cell-to-target ratios are 1.25:1, 0.625:1, and 0.312:1. The gray triangles are results from LIR1NK
cells; black squares are the results from LIRNK cells. Each data point represents 3 independent readouts. The data were analyzed using two-way ANOVA, error
bars represent SEM, and significant results (*, P 0.05; **, P 0.01) are indicated.
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strong correlation between the acquisition of HCMV infection
and an increase in the frequency of NKG2C-expressing NK cells in
peripheral blood (37–43), and one report has suggested that
NKG2C binds with UL18 at very low affinity (36). Although no
reports to date have shown differential control between NKG2C
and NKG2CNK cells of HCMV in standard cytotoxic assays, one
recent report does suggest that NKG2Cbright NK cells exhibit
higher degranulation against target cells in the presence of serum
containing HCMV-specific antibodies (44).
We therefore investigated whether NKG2C NK cells medi-
ated better control of HCMV in our viral dissemination assay.
Since we had already shown that LIR1 expression affected NK-
mediated control of viral spread, cells were sorted into four sub-
sets based on both LIR1 and NKG2C expression (Fig. 5A). We also
analyzed activated NK cell lines with anti-NKG2A, -NKG2C, and
-LIR 1 in order to determine the distribution of the inhibitory NK
cell receptor NKG2A from four different donors (2 HCMV-sero-
positive and 2 HCMV-seronegative donors). The results show
that there was no or negligible expression of inhibitory receptor
NKG2A (HCMV seropositive, 0.4% and 1.1%; HCMV seronega-
FIG 5 The expression of NKG2C on in vitro-expanded NK cells has an effect on NK cell effector functions. (A) In vitro-expanded NK cells were stained with
anti-CD3, -CD56, -LIR1, and -NKG2C antibodies and sorted by flow cytometry into four subsets based on LIR1 and NKG2C expressions. CD56CD3NK cells
were first collected (NK) before further sorting into LIR1 NKG2C, LIR1 NKG2C, LIR1 NKG2C, and LIR1 NKG2C. Representative dot plots of the
NK cells before and after sorting are shown. Sorted NK cells were then cocultured with K562 targets (B) or HFFs infected with TB40/e at MOI of 5 (C). The NK
cell-to-target ratio is 1:1. The percentages of CD107a cells were measured by flow cytometry after 5 h, and the levels of CCL4 cytokine secretion by NK cells were
measured after overnight incubation. NK cell only and target cell only are the control samples. Error bars represent SEM. The experiment was repeated using 3
different donor NK cells (n 3), and the average results were analyzed by the Student t test. Significant results (*, P 0.05) are indicated.
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tive, 0% and 5%) in cells, and as such it was unlikely to have a
significant impact on the functional assay.
To ensure that these subsets maintained their effector func-
tions postsorting, their cytotoxicity (CD107a degranulation) and
cytokine secretion against K562 target cells were determined. Both
LIR1NKG2C and LIR1 NKG2C NK cells degranulated sig-
nificantly more strongly than the LIR1 NKG2C and LIR1
NKG2C NK cells, i.e., NK cell subsets expressing the NKG2C-
activating receptor had higher cytotoxicity toward K562 target
cells than subsets without NKG2C (Fig. 5B, left); however, expres-
sion of LIR1 made little difference in this effector assay. The cyto-
kine release assay showed no significant differences between any
NK cell subsets (Fig. 5B, right). Interestingly, these results sug-
gested that different NK cell effector mechanisms could be inde-
pendently activated.
The four NK cell subsets were also cocultured with strain
TB40/e-infected target cells, and CD107a and cytokine responses
were measured. All of the subsets displayed low cytotoxicity
against TB40/e-infected fibroblasts (Fig. 5C, left), similar to re-
sults from previous studies using in vitro-expanded NK cell lines
(24, 53). In contrast, the cytokine release assay showed that al-
though all subsets maintained their CCL4 production in response
to TB40/e-infected fibroblasts, NKG2CNK cell subsets had sig-
nificantly higher CCL4 secretion than did NKG2C subsets (P
0.05), irrespective of LIR1 expression (Fig. 5C, right). Together,
these results suggested that expression of NKG2C enhances CCL4
release by NK cells when interacting with TB40/e-infected target
cells but that the induction of cytokine release does not correlate
with NK cell degranulation.
The 4 NK subsets were also used simultaneously in a VDA (Fig.
6) using NK cells from four independent donors. In good agree-
ment with our earlier results, NK cell subsets with LIR1 expres-
sion, with or without NKG2C, resulted in a lower percentage of
viral spread than cells without LIR1 (Fig. 6A). This was observed
across all the donors tested. However, when we compared the
NKG2C NK cell subsets against NKG2C NK cell subsets, with
or without LIR1 expression, three of four donors tested showed no
difference in the degree of HCMV control (Fig. 6B). In one donor,
the LIR1 NKG2C subset exerted worse control than did the
LIR1 NKG2C NK subset (Fig. 6B, left column), while with
FIG 6 Expression of NKG2C on in vitro-expanded NK cells does not control HCMV dissemination more effectively over the long term. Viral dissemination
assays were carried out using the NK cells sorted based on LIR1 and NKG2C as previously described and incubated with TB40/e-infected HFFs at an MOI of 0.1.
The experiment was repeated four times using NK cells from four different donors. The NK cell-to-target ratios are 1.25:1, 0.625:1, and 0.312:1. The results were
analyzed using flow cytometry and then normalized according to uninfected and infected controls. On each graph, the circle represents LIR1NKG2CNK cells;
the rectangle represents LIR NKG2C NK cells; the upward triangle represents LIR1 NKG2C NK cells; and downward triangle represents LIR1 NKG2C
NK cells. The comparison of LIR1-expressing and LIR1-nonexpressing subsets are shown in panel A, while the comparison of NKG2C-expressing and NKG2C-
nonexpressing subsets are shown in panel B. Each data point represents 3 independent readouts. The data were analyzed using two-way ANOVA, error bars
represent SEM, and significant results (*, P 0.05; **, P 0.01) are indicated.
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another donor, the LIR1 NKG2C NK subset exerted better
control than LIR1 NKG2C NK cells (Fig. 6B, right column).
However, taken together, we concluded that there is no clear dif-
ference in the degree of HCMV dissemination when NK cells ex-
press or lack NKG2C on their surface.
DISCUSSION
To date, 10 HCMV gene products and one HCMV microRNA
have been shown to interfere with NK cell immune responses, by
disrupting both activating and inhibitory signaling to NK cells
during HCMV lytic infection (19, 20). Studies into the activity of
NK cells in vitro against HCMV-infected cells have predominantly
focused on effector mechanisms such as cytokine production and
cytotoxicity (28, 35). Moreover, although the frequency of NK
cells expressing several NK receptors is associated with HCMV
serostatus (37, 39, 58), enhancement in NK cell effector functions
has been demonstrated only in the presence of anti-HCMV anti-
bodies (41). Currently there is little in vitro evidence to suggest
that these higher-frequency NK cell subsets confer better control
of HCMV in longer-term culture.
A viral dissemination assay that we had previously used to
study CD8 T cell responses (51) was established to test NK cell
responses against fibroblasts lytically infected with HCMV. This
was similar in concept to a recently published focal expansion
assay (45) that was used to investigate the control of viral spread by
NK cells during HCMV TB40/e infection and the effect of deletion
of known viral NK immune evasion genes. This work concluded
that NK cells can efficiently control HCMV transmission in dif-
ferent cell types and the UL16 viral protein contributes to the
immune evasion of NK cells during HCMV transmission. The
focal expansion assay and the viral dissemination assay are new
methodological approaches employed for studying the longer-
term interaction between NK cells and HCMV-infected cells in
vitro. Compared with conventional NK cell cytotoxicity and de-
granulation assays, both focal expansion and viral dissemination
assays aim to assess the longer-term control of NK cells on HCMV
infection by indirectly measuring changes in the spread of virus in
the presence of NK cells. While we did not investigate which NK
cell effector mechanisms (either cytokine secretion or direct cell
cytotoxicity or both) are effective at limiting growth and dissem-
ination of HCMV in our VDA, it has been demonstrated by Wu
et al. (45) that during long-term coincubation of NK cells with
HCMV-infected target cells, both direct cell contact and soluble
factors like IFN-
 are contributing factors to the control of dis-
semination (45).
Our assay shows that NK cells can exert effector functions at an
E/T ratio as low as 0.3125:1, which is considerably lower and more
physiological than results from short-term NK cell cytotoxicity
and degranulation assays, which often required an E/T ratio of
10:1 and higher. Our data support the hypothesis that NK cells
control low-passage-number strains such as Merlin less effectively
than high-passage-number laboratory mutants such as AD169;
this is expected, as AD169 is lacking several immune evasion genes
(59, 60). TB40/e is known to contain a mixture of virus popula-
tions, including some that lack a functional UL141 (an established
NK immune evasion gene) (53, 61), and also contains a nonfunc-
tional UL40 gene (62). Thus, it was interesting that the dissemi-
nation assay was also able to distinguish between NK cell control
of infections with TB40/e and Merlin, underlining the advantages
of working with defined strains that express a full complement of
HCMV genes when characterizing viral pathogenesis.
Importantly, our assay demonstrated for the first time that the
ability of in vitro-expanded, activated LIR1 NK cells to inhibit
viral dissemination differed from that of LIR1 NK cells and was
dependent on natural sequence variation within the ligands ex-
pressed by a viral strain. These strain differences are likely due to
the differences in the binding kinetics exhibited by UL18 proteins
from different HCMV strains to LIR-1 (63, 64). Vales-Gomez
et al. demonstrated that a particular isolate of the UL18 protein,
variant E, which has amino acid sequences in the 3 region iden-
tical to those of strain Merlin UL18, showed a binding affinity that
was at least 50-fold lower than the UL18 protein from AD169 (63).
They also demonstrated that the UL18 protein of variant E exhib-
ited weaker inhibition against an LIR1-expressing transformed
NK cell line than the UL18 derived from AD169 (63). A separate
study carried out by Cerboni et al. also showed that purified
AD169 UL18 protein was able to inhibit cytotoxicity of the NKL
cell line to a greater extent than UL18 protein from a clinical
isolate, which again had the same 3 sequence as that found in
strain Merlin (64). Interestingly, the three amino acids that we
identified as responsible for the differing abilities of NK cells to
control dissemination have recently been shown to be under pos-
itive selection in HCMV strains, toward the more-inhibitory se-
quence (65), suggesting that the need to avoid activating NK cells
can directly drive virus evolution.
Given the above considerations, it seems likely that UL18 from
both the Merlin and TB40/e strains have weaker affinity for LIR1
than for AD169, and as a result LIR1 NK cells received weaker
inhibitory signals than from the AD169 strain and were therefore
better at controlling HCMV dissemination. It is also possible that
UL18 of TB40/e/Merlin also interacts with other NK receptors
(leading to enhancement in NK cell function), which have yet to
be identified. Alternatively, instead of inducing weaker inhibition
signaling via LIR1, the UL18 protein of Merlin/TB40/e might
cause a change in clustering of LIR1 and “antagonize” inhibitory
signaling. This antagonistic ligand behavior had been suggested in
certain peptide-MHC-KIR interactions between HCV and NK
cells (66), although the mechanism has yet to be fully established.
Lastly, we examined the effect of expression of the activating
receptor NKG2C (67). An increase in the proportion of NKG2C
NK cells is strongly associated with HCMV serostatus (37, 38, 40,
43, 68). However, there is as yet no evidence to suggest that the
acquisition of NKG2C on NK cells without the presence of anti-
HCMV antibodies confers a stronger immune response against
HCMV infection. More recently, another study demonstrated
that although HCMV-seropositive patients receiving allogeneic
stem cell transplantations have higher proportions of NKG2C
NK cells, there is no obvious change in NKG2CNK cells between
patients with or without HCMV DNAemia 60 days after trans-
plantation (42). In accordance with this, our results showed no
differences between NKG2C and NKG2C NK cell subsets in
their ability to directly control HCMV dissemination (despite
NKG2C expression being able to enhance CCL4 cytokine produc-
tion), suggesting that there may not be a specific functional role
for NKG2C in the direct control of HCMV. However, in light of
recent published work suggesting that the presence of HCMV-
seropositive donor serum can induce stronger responses of
NKG2Cbright NK cells in the short-term assay (44), it would be
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interesting to assess if the donor serum can influence the outcome
of these long-term dissemination assays.
In summary, we have presented here an improved, in vitro
technique of assessing long-term immune control of NK cells
against HCMV dissemination. Conventional NK cell cytotoxicity
assays focus on the NK cell responses within a few hours of cocul-
tures with target cells. The VDA uses a much lower, more physi-
ological E/T ratio than conventional NK cytotoxicity assays and
extends the analysis of NK cell responses to 9 days. Through the
viral dissemination assay, we have uncovered new evidence that
NK cell subsets respond differently to different variants of viral
ligands, but the expression of NKG2C made little difference to the
outcome of the long-term HCMV control by NK cells. The VDA
could be adapted to analyze other NK cell subsets that have been
indicated as “memory-like” and assess whether their in vitro con-
trol over virus spreading may be similar to that described previ-
ously for the murine Ly49H activating receptor and MCMV m157
protein (69). Taken together, these data give the first description
of a number of novel interactions between NK cells and HCMV
during long-term lytic life cycles. These results may have implica-
tions for susceptibility to HCMV infection and to future ap-
proaches to vaccination strategies that involve the generation of
immunological memory-like responses of NK cells.
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